Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …

The evolving paradigm of continuous therapy and maintenance treatment approaches in
multiple myeloma (MM) offers prolonged disease control and improved outcomes compared …

We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-
house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study …

Multiple myeloma is a disease typical of the elderly, and, because of the increase in life
expectancy of the general population, its incidence is expected to grow in the future. Elderly …

Multiple myeloma is the second most frequent hematological disease. The introduction of
melphalan as high-dose therapy followed by autologous hematopoietic cell transplantation …